PANCREATIC CANCER PATIENTS ARE COUNTING ON YOU

Increase Funding for the Pancreatic Cancer Research Program at the DoD to $20 million

WHY IS THIS URGENT?

Pancreatic cancer is the world’s toughest cancer.

• The five-year survival rate for pancreatic cancer is just 13%.1
• Pancreatic cancer is the 3rd leading cause of cancer-related deaths in the U.S., and it’s projected to move to 2nd by 2030.1,2
• In 2023, an estimated 66,450 Americans will be diagnosed with pancreatic cancer, and 51,750 will die from the disease.1

WHY PCARP?

Increasing funding for the Pancreatic Cancer Research Program at the DoD is an opportunity to quickly and dramatically impact patient outcomes.

“DoD support tends to favor innovative ideas...And, oftentimes, when you take those higher risk choices – that is usually when you make a more significant and perhaps unexpected discovery.”

Channing Der, PhD
Federally Funded Pancreatic Cancer Researcher
Member, PanCAN Scientific and Medical Advisory Board
Professor, University of North Carolina

WHY INVEST?

Funding is not keeping pace with the tremendous opportunity indicated by the scientific community.

In FY22, 207 scientists submitted promising research ideas to the program to advance scientific knowledge. Of those, 55 were invited to submit competitive full grant applications, and only 13 were able to be funded.5*

Highly meritorious research that could lead to breakthroughs for pancreatic cancer patients is going unfunded. Congress can change this by increasing the investment for FY24.

5. Congressionally Directed Medical Research Programs (CDMRP) Pancreatic Cancer Research Program, FY22 Award Applications Recommended for Funding (accessed June 2023). *These numbers reflect recommendations only.